Uploaded by FinancialNewsOnline on Nov 22, 2011
Medtronic (NYSE:MDT) reported Q2 EPS of $0.84, beating analyst estimates of $0.82 per share. Revenues for the quarter rose 5.9% year-over-year to $4.13 billion, topping consensus estimates of $4.07 billion.
Chairman and CEO Omar Ishrak said in a statement, "I'm pleased we delivered another quarter of consistent growth in a difficult environment. A majority of our businesses, and nearly all of our geographies, contributed to this growth. As we continue to focus on innovation, globalization, and execution, I see tremendous opportunities for growth in the future."
Medtronic (NYSE:MDT) has potential upside of 19.6% based on a current price of $33.27 and an average consensus analyst price target of $39.78.
Chairman and CEO Omar Ishrak said in a statement, "I'm pleased we delivered another quarter of consistent growth in a difficult environment. A majority of our businesses, and nearly all of our geographies, contributed to this growth. As we continue to focus on innovation, globalization, and execution, I see tremendous opportunities for growth in the future."
Medtronic (NYSE:MDT) has potential upside of 19.6% based on a current price of $33.27 and an average consensus analyst price target of $39.78.
No comments:
Post a Comment